Disease Landscape and Forecast Insights

The success of biologics will greatly depend on payers because they are the ones who determine which products gain formulary access and preferential reimbursement. Understanding the factors that…

MARKET OUTLOOK Sepsis is a life-threatening organ dysfunction resulting from a dysregulated host response to infection. It is one of the leading causes of death among developed countries, with…

MARKET OUTLOOK The primary goal of UC treatment is to induce and maintain remission with little to no clinical symptoms remaining. Conventional therapies (5-ASAs, corticosteroids) are typically…

MARKET OUTLOOK The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population who cannot be adequately controlled with topical…

MARKET OUTLOOK  Asthma pharmacotherapy has two main goals: to address underlying airways inflammation and promote bronchodilation. Physicians use two types of therapy to achieve these goals:…

Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary…

The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…

Diabetic retinopathy (DR) is an ophthalmic complication of diabetes. In the advanced stages of DR, leaking fluid from abnormal blood vessels can cause the macula to swell, impacting sharp vision…

Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and the novel…

The COPD treatment algorithm continues to evolve, with changing recommendations on the use of ICS s, LABA / ICS FDC s, and LABA / LAMA FDC s. This study reveals which therapies are prescribed first…

For the estimated 5 million people in the United States with atrial fibrillation, several treatment approaches can be utilized, each with a wide range of available pharmacological options. The AHA…

Venclexta (Wave 3) is the third in a multiwave series designed to track physician perception and uptake of as well as the competitive environment for the newly launched chronic lymphocytic leukemia…